Literature DB >> 33318008

Rifabutin Is Inactivated by Mycobacterium abscessus Arr.

Daniel Schäfle1, Petra Selchow1, Barbara Borer1, Michael Meuli1, Anna Rominski1, Bettina Schulthess1,2, Peter Sander3,2.   

Abstract

Mycobacterium abscessus exhibits Arr (ADP-ribosyltransferase)-dependent rifampin resistance. In apparent contrast, rifabutin (RBT) has demonstrated promising activity in M. abscessus infection models, implying that RBT might not be inactivated by Arr. RBT susceptibility testing of M. abscessus Δarr revealed a strongly decreased MIC. Our findings suggest that the efficacy of RBT might be enhanced by rendering RBT resilient to Arr-dependent modification or by blocking M. abscessus Arr activity.
Copyright © 2021 American Society for Microbiology.

Entities:  

Keywords:  ADP-ribosyltransferase; Mycobacterium; Mycobacterium abscessus; cystic fibrosis; resistance; rifabutin; rifampicin; rifamycin

Mesh：

Substances：

Year:  2021        PMID： 33318008      PMCID： PMC8092531          DOI： 10.1128/AAC.02215-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  28 in total

Review 1.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

2.  Elucidation of Mycobacterium abscessus aminoglycoside and capreomycin resistance by targeted deletion of three putative resistance genes.

Authors:  Anna Rominski; Petra Selchow; Katja Becker; Juliane K Brülle; Michael Dal Molin; Peter Sander
Journal:  J Antimicrob Chemother       Date:  2017-08-01       Impact factor: 5.790

3.  Structural mechanism for rifampicin inhibition of bacterial rna polymerase.

Authors:  E A Campbell; N Korzheva; A Mustaev; K Murakami; S Nair; A Goldfarb; S A Darst
Journal:  Cell       Date:  2001-03-23       Impact factor: 41.582

4.  New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases.

Authors:  Keith D Combrink; Daniel A Denton; Susan Harran; Zhenkun Ma; Katrina Chapo; Dalai Yan; Eric Bonventre; Eric D Roche; Timothy B Doyle; Gregory T Robertson; Anthony S Lynch
Journal:  Bioorg Med Chem Lett       Date:  2006-10-12       Impact factor: 2.823

5.  Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus and Mycobacteriumabscessus subsp. bolletii and designation of Mycobacteriumabscessus subsp. massiliense comb. nov.

Authors:  Enrico Tortoli; Thomas A Kohl; Barbara A Brown-Elliott; Alberto Trovato; Sylvia Cardoso Leão; Maria Jesus Garcia; Sruthi Vasireddy; Christine Y Turenne; David E Griffith; Julie V Philley; Rossella Baldan; Silvia Campana; Lisa Cariani; Carla Colombo; Giovanni Taccetti; Antonio Teri; Stefan Niemann; Richard J Wallace; Daniela M Cirillo
Journal:  Int J Syst Evol Microbiol       Date:  2016-08-04       Impact factor: 2.747

6.  High Levels of Intrinsic Tetracycline Resistance in Mycobacterium abscessus Are Conferred by a Tetracycline-Modifying Monooxygenase.

Authors:  Paulami Rudra; Kelley Hurst-Hess; Pascal Lappierre; Pallavi Ghosh
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

Review 7.  New β-lactamase inhibitors: a therapeutic renaissance in an MDR world.

Authors:  Sarah M Drawz; Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2013-12-30       Impact factor: 5.191

8.  Rifabutin Is Active against Mycobacterium abscessus Complex.

Authors:  Dinah Binte Aziz; Jian Liang Low; Mu-Lu Wu; Martin Gengenbacher; Jeanette W P Teo; Véronique Dartois; Thomas Dick
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

9.  Rifabutin Is Active against Mycobacterium abscessus in Mice.

Authors:  Thomas Dick; Sung Jae Shin; Won-Jung Koh; Véronique Dartois; Martin Gengenbacher
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191
View more
  3 in total

1.  Ribosome Protection as a Mechanism of Lincosamide Resistance in Mycobacterium abscessus.

Authors:  Kelley R Hurst-Hess; Paulami Rudra; Pallavi Ghosh
Journal:  Antimicrob Agents Chemother       Date:  2021-08-30       Impact factor: 5.191

2.  Kanglemycin A Can Overcome Rifamycin Resistance Caused by ADP-Ribosylation by Arr Protein.

Authors:  John Harbottle; Hamed Mosaei; Nicholas Allenby; Nikolay Zenkin
Journal:  Antimicrob Agents Chemother       Date:  2021-10-04       Impact factor: 5.938

3.  Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessus.

Authors:  Uday S Ganapathy; Tian Lan; Philipp Krastel; Marissa Lindman; Matthew D Zimmerman; HsinPin Ho; Jansy P Sarathy; Joanna C Evans; Véronique Dartois; Courtney C Aldrich; Thomas Dick
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.